Department of Neurology Heidelberg University Hospital, Heidelberg, Germany.
Department of Radiology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Eur J Neurol. 2022 Sep;29(9):2664-2673. doi: 10.1111/ene.15410. Epub 2022 Jun 17.
Endovascular therapy (EVT) is increasingly reported for treatment of isolated posterior cerebral artery (PCA) occlusions although its clinical benefit remains uncertain. This study-level meta-analysis investigated the functional outcomes and safety of EVT and best medical management (BMM) compared to BMM alone for treatment of PCA occlusion stroke.
We conducted a literature search in PubMed, Web of Science and Embase for studies in patients with isolated PCA occlusion stroke treated with EVT + BMM or BMM including intravenous thrombolysis. There were no randomized trials and all studies were retrospective. The primary outcome was modified Rankin Scale score of 0-2 at 3 months, while safety outcomes included mortality rate and incidence of symptomatic intracranial hemorrhage (sICH).
Twelve studies with a total of 679 patients were included in the meta-analysis: 338 patients with EVT + BMM and 341 patients receiving BMM alone. Good functional outcome at 3 months was achieved in 58.0% (95% confidence interval [CI] 43.83-70.95) of patients receiving EVT + BMM and 48.1% (95% CI 40.35-55.92) of patients who received BMM alone, with respective mortality rates of 12.6% (95% CI 7.30-20.93) and 12.3% (95% CI 8.64-17.33). sICH occurred in 4.2% (95% CI 2.47-7.03) of patients treated with EVT + BMM and 3.2% (95% CI 1.75-5.92) of patients treated with BMM alone. Comparative analyses were performed on studies that included both treatments and these demonstrated no significant differences.
Our results demonstrate that EVT represents a safe treatment for patients with isolated PCA occlusion stroke. There were no differences in clinical or safety outcomes between treatments, supporting randomization of future patients into distal vessel occlusion trials.
尽管血管内治疗(EVT)治疗孤立性大脑后动脉(PCA)闭塞的临床获益仍不确定,但越来越多的报道表明其具有治疗作用。本研究级别的荟萃分析旨在评估 EVT 联合最佳药物治疗(BMM)与单纯 BMM 治疗孤立性 PCA 闭塞性卒中的功能结局和安全性。
我们在 PubMed、Web of Science 和 Embase 中进行了文献检索,纳入接受 EVT+BMM 或包括静脉溶栓在内的单纯 BMM 治疗的孤立性 PCA 闭塞性卒中患者的研究。本研究中没有随机试验,所有研究均为回顾性研究。主要结局为 3 个月时改良 Rankin 量表评分 0-2 分,安全性结局包括死亡率和症状性颅内出血(sICH)发生率。
纳入 12 项研究共 679 例患者,其中 338 例患者接受 EVT+BMM,341 例患者接受单纯 BMM 治疗。接受 EVT+BMM 的患者 3 个月时功能预后良好的比例为 58.0%(95%CI 43.83-70.95),接受单纯 BMM 的患者为 48.1%(95%CI 40.35-55.92),死亡率分别为 12.6%(95%CI 7.30-20.93)和 12.3%(95%CI 8.64-17.33)。接受 EVT+BMM 的患者 sICH 发生率为 4.2%(95%CI 2.47-7.03),接受单纯 BMM 的患者为 3.2%(95%CI 1.75-5.92)。我们对同时包含两种治疗的研究进行了对比分析,结果未显示出显著差异。
本研究结果表明,EVT 是治疗孤立性 PCA 闭塞性卒中的一种安全治疗方法。两种治疗方法在临床结局和安全性方面无差异,支持未来将患者随机分配到远端血管闭塞试验中。